Dynamics and potential impact of the immune response to chronic myelogenous leukemia.
Recent mathematical models have been developed to study the dynamics of chronic myelogenous leukemia (CML) under imatinib treatment. None of these models incorporates the anti-leukemia immune response. Recent experimental data show that imatinib treatment may promote the development of anti-leukemia...
Main Authors: | Peter S Kim, Peter P Lee, Doron Levy |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2008-06-01
|
Series: | PLoS Computational Biology |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18566683/pdf/?tool=EBI |
Similar Items
-
Chronic myelogenous leukemia in Libya
by: Itrat Mehdi, et al.
Published: (2012-07-01) -
Chronic myelogenous leukemia on target
by: Veronika Némethová, et al.
Published: (2018-07-01) -
Bosutinib in the management of chronic myelogenous leukemia
by: Keller-von Amsberg G, et al.
Published: (2013-05-01) -
Apoptosis resistance in chronic myelogenous leukemia
by: Fabíola Attié de Castro, et al.
Published: (2005-09-01) -
CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE ELDERLY
by: Lodovico Balducci
Published: (2014-05-01)